131 related articles for article (PubMed ID: 33415451)
21. Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis.
Dekkers JS; Bergstra SA; Chopra A; Tikly M; Fonseca JE; Salomon-Escoto K; Huizinga TWJ; van der Woude D
Rheumatology (Oxford); 2019 Jan; 58(1):149-153. PubMed ID: 30204896
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
23. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
Verstappen M; van Steenbergen HW; de Jong PHP; van der Helm-van Mil AHM
Arthritis Res Ther; 2022 Jan; 24(1):4. PubMed ID: 34980246
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
25. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
26. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
27. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
Boman A; Brink M; Lundquist A; Hansson M; Mathsson-Alm L; Rönnelid J; Berglin E; Holmdahl R; Skriner K; Serre G; Klareskog L; Rantapää-Dahlqvist S
RMD Open; 2019; 5(2):e000946. PubMed ID: 31565241
[TBL] [Abstract][Full Text] [Related]
28. Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
Xie W; Huang H; Li G; Hao Y; Gui Y; Wang Y; Deng X; Zhao J; Geng Y; Ji L; Zhang X; Song Z; Zhang Z
Ann Rheum Dis; 2021 Aug; 80(8):997-1003. PubMed ID: 33811037
[TBL] [Abstract][Full Text] [Related]
29. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
[TBL] [Abstract][Full Text] [Related]
30. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.
Bugatti S; Bogliolo L; Vitolo B; Manzo A; Montecucco C; Caporali R
Arthritis Res Ther; 2016 Oct; 18(1):226. PubMed ID: 27716332
[TBL] [Abstract][Full Text] [Related]
31. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.
Baganz L; Richter A; Albrecht K; Schneider M; Burmester GR; Zink A; Strangfeld A
Semin Arthritis Rheum; 2019 Jun; 48(6):976-982. PubMed ID: 30316460
[TBL] [Abstract][Full Text] [Related]
32. In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register.
Verstappen SM; Lunt M; Bunn DK; Scott DG; Symmons DP
Ann Rheum Dis; 2011 Aug; 70(8):1428-32. PubMed ID: 21551505
[TBL] [Abstract][Full Text] [Related]
33. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
34. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
35. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
36. [Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up].
Aronova ES; Lukina GV; Glukhova SI; Gridneva GI; Kudryavtseva AV
Ter Arkh; 2020 Jun; 92(5):39-45. PubMed ID: 32598774
[TBL] [Abstract][Full Text] [Related]
37. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
38. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients.
Iannone F; Fanizzi R; Notarnicola A; Scioscia C; Anelli MG; Lapadula G
Joint Bone Spine; 2015 May; 82(3):187-91. PubMed ID: 25619156
[TBL] [Abstract][Full Text] [Related]
39. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
40. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
Aletaha D; Alasti F; Smolen JS
Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
